{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:03Z","timestamp":1787020803491,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["184452"],"award-info":[{"award-number":["184452"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danone, Nutricia Metabolics","award":["000"],"award-info":[{"award-number":["000"]}]},{"name":"Bangerter Rhyner Foundation","award":["000"],"award-info":[{"award-number":["000"]}]},{"name":"von Tobel Foundation","award":["000"],"award-info":[{"award-number":["000"]}]},{"name":"Clinical Trial Unit, University of Bern","award":["000"],"award-info":[{"award-number":["000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The population of adult patients with early-treated phenylketonuria (PKU) following newborn screening is growing substantially. The ideal target range of blood phenylalanine (Phe) levels in adults outside pregnancy is a matter of debate. Therefore, prospective intervention studies are needed to evaluate the effects of an elevated Phe concentration on cognition and structural, functional, and neurometabolic parameters of the brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PICO (Phenylalanine and Its Impact on Cognition) Study evaluates the effect of a 4-week Phe load on cognition and cerebral parameters in adults with early-treated PKU in a double-blind, randomized, placebo-controlled, crossover, noninferiority trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Thirty adult patients with early-treated PKU and 30 healthy controls comparable to patients with regard to age, sex, and educational level will be recruited from the University Hospitals Bern and Zurich, Switzerland. Patients are eligible for the study if they are 18\u2009years of age or older and had PKU diagnosed after a positive newborn screening and were treated with a Phe-restricted diet starting within the first 30\u2009days of life.<\/jats:p>\n                    <jats:p>Intervention: The cross-over intervention consists of 4-week oral Phe or placebo administration in patients with PKU. The study design mimics a Phe-restricted and a Phe-unrestricted diet using a double-blinded, placebo-controlled approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The primary objective of the PICO Study is to prospectively assess whether a temporarily elevated Phe level influences cognitive performance (working memory assessed with a n-back task) in adults with early-treated PKU. As a secondary objective, the PICO Study will elucidate the cerebral (fMRI, neural activation during a n-back task; rsfMRI, functional connectivity at rest; DTI, white matter integrity; and ASL, cerebral blood flow) and neurometabolic mechanisms (cerebral Phe level) that accompany changes in Phe concentration. Cognition, and structural and functional parameters of the brain of adult patients with early-treated PKU will be cross-sectionally compared to healthy controls. All assessments will take place at the University Hospital Bern, Switzerland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Randomization<\/jats:title>\n                    <jats:p>Central randomization will be used to assign participants to the different treatment arms with age, sex, and center serving as the stratification factors. Randomization lists will be generated by an independent statistician.<\/jats:p>\n                    <jats:p>Blinding: All trial personnel other than the statistician generating the randomization list and the personnel at the facility preparing the interventional product are blinded to the assigned treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Using a combination of neuropsychological and neuroimaging data, the PICO Study will considerably contribute to improve the currently insufficient level of evidence on how adult patients with early-treated PKU should be managed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The study is registered at clinicaltrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=NCT03788343\">NCT03788343<\/jats:ext-link>\n                      )\u00a0on the 27th of December\u00a02018, at kofam.ch (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.kofam.ch\/de\/studienportal\/suche\/0\/studie\/44815\">SNCTP000003117<\/jats:ext-link>\n                      )\u00a0on the 17th of December 2018, and on the International Clinical Trials Registry Platform of the WHO.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-019-4022-z","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T09:02:47Z","timestamp":1581584567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Roman","family":"Trepp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Muri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Abgottspon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Bosanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Hochuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Slotboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6556-3419","authenticated-orcid":false,"given":"Regula","family":"Everts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"issue":"9750","key":"4022_CR1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, Van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417\u201327.","journal-title":"Lancet"},{"key":"4022_CR2","doi-asserted-by":"crossref","unstructured":"Pers S, Gautschi M, Nuoffer J, Schwarz H, Christ E. Integration of adult patients with phenylketonuria into professional life: long-term follow-up of 27 patients in a single centre in Switzerland. Swiss Med Wkly. 2014;(December):1\u20136 http:\/\/doi.emh.ch\/smw.2014.14074.","DOI":"10.4414\/smw.2014.14074"},{"issue":"9","key":"4022_CR3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-8587(17)30201-2","volume":"5","author":"P Burgard","year":"2017","unstructured":"Burgard P, Ullrich K, Ballhausen D, Hennermann JB, Hollak CEM, Langeveld M, et al. Issues with European guidelines for phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):681\u20133.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"4022_CR4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10519-017-9863-1","volume":"47","author":"R Jahja","year":"2017","unstructured":"Jahja R, van Spronsen FJ, de Sonneville LMJ, van der Meere JJ, Bosch AM, Hollak CEM, et al. Long-term follow-up of cognition and mental health in adult phenylketonuria: a PKU-COBESO study. Behav Genet. 2017;47(5):486\u201397.","journal-title":"Behav Genet."},{"issue":"3","key":"4022_CR5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/neu0000336","volume":"31","author":"C Romani","year":"2017","unstructured":"Romani C, Palermo L, MacDonald A, Limback E, Hall SK, Geberhiwot T. The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: effects across tasks and developmental stages. Neuropsychology. 2017;31(3):242\u201354 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28240926.","journal-title":"Neuropsychology"},{"issue":"1","key":"4022_CR6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-018-0893-4","volume":"13","author":"DL Hofman","year":"2018","unstructured":"Hofman DL, Champ CL, Lawton CL, Henderson M, Dye L. A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet J Rare Dis. 2018;13(1):150 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30165883.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4022_CR7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2307\/1130832","volume":"61","author":"MC Welsh","year":"1990","unstructured":"Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ERB. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev. 1990;61(6):1697 https:\/\/www.jstor.org\/stable\/1130832?origin=crossref.","journal-title":"Child Dev"},{"issue":"5","key":"4022_CR8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/B:BOLI.0000042985.02049.ff","volume":"27","author":"VL Brumm","year":"2004","unstructured":"Brumm VL, Azen C, Moats RA, Stern AM, Broomand C, Nelson MD, et al. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J Inherit Metab Dis. 2004;27(5):549\u201366.","journal-title":"J Inherit Metab Dis."},{"issue":"3","key":"4022_CR9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymgme.2012.08.007","volume":"107","author":"KE Bodner","year":"2012","unstructured":"Bodner KE, Aldridge K, Moffitt AJ, Peck D, White DA, Christ SE. A volumetric study of basal ganglia structures in individuals with early-treated phenylketonuria. Mol Genet Metab. 2012;107(3):302\u20137.","journal-title":"Mol Genet Metab."},{"issue":"5","key":"4022_CR10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10545-011-9439-9","volume":"35","author":"SE Christ","year":"2012","unstructured":"Christ SE, Moffitt AJ, Peck D, White DA, Hilgard J. Decreased functional brain connectivity in individuals with early-treated phenylketonuria: evidence from resting state fMRI. J Inherit Metab Dis. 2012;35(5):807\u201316.","journal-title":"J Inherit Metab Dis."},{"issue":"3","key":"4022_CR11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10545-011-9318-4","volume":"34","author":"B Sundermann","year":"2011","unstructured":"Sundermann B, Pfleiderer B, M\u00f6ller HE, Schwindt W, Weglage J, Lepsien J, et al. Tackling frontal lobe\u2013related functions in PKU through functional brain imaging: a Stroop task in adult patients. J Inherit Metab Dis. 2011;34(3):711\u201321 http:\/\/link.springer.com\/10.1007\/s10545-011-9318-4.","journal-title":"J Inherit Metab Dis"},{"issue":"SUPPL","key":"4022_CR12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.ymgme.2011.09.036","volume":"104","author":"FJ Van Spronsen","year":"2011","unstructured":"Van Spronsen FJ, Huijbregts SCJ, Bosch AM, Leuzzi V. Cognitive, neurophysiological, neurological and psychosocial outcomes in early-treated PKU-patients: a start toward standardized outcome measurement across development. Mol Genet Metab. 2011;104(SUPPL):S45\u201351. https:\/\/doi.org\/10.1016\/j.ymgme.2011.09.036.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4022_CR13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1037\/neu0000337","volume":"31","author":"L Palermo","year":"2017","unstructured":"Palermo L, Geberhiwot T, MacDonald A, Limback E, Hall SK, Romani C. Cognitive outcomes in early-treated adults with phenylketonuria (PKU): a comprehensive picture across domains. Neuropsychology. 2017;31(3):255\u201367 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28080075.","journal-title":"Neuropsychology"},{"issue":"1\u20132","key":"4022_CR14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","volume":"92","author":"SE Waisbren","year":"2007","unstructured":"Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: A systematic literature review and meta-analysis. Mol Genet Metab. 2007;92(1\u20132):63\u201370.","journal-title":"Mol Genet Metab."},{"issue":"SUPPL","key":"4022_CR15","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ymgme.2009.10.007","volume":"99","author":"SE Christ","year":"2009","unstructured":"Christ SE, Huijbregts SCJ, de Sonneville LMJ, White DA. Executive function in early-treated phenylketonuria: Profile and underlying mechanisms. Mol Genet Metab. 2009;99(SUPPL):S22\u201332. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.007.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4022_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ymgme.2010.10.003","volume":"102","author":"M Bik-Multanowski Miroslaw","year":"2011","unstructured":"Bik-Multanowski Miroslaw M, Pietrzyk JJ, Mozrzymas R. Routine use of CANTAB system for detection of neuropsychological deficits in patients with PKU. Mol Genet Metab. 2011;102(2):210\u20133. https:\/\/doi.org\/10.1016\/j.ymgme.2010.10.003.","journal-title":"Mol Genet Metab"},{"key":"4022_CR17","doi-asserted-by":"crossref","unstructured":"Baddeley A. Working memory. Science. 1992;255(5044):556\u20139.","DOI":"10.1126\/science.1736359"},{"issue":"7","key":"4022_CR18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1467-9280.2007.01948.x","volume":"18","author":"MJ Kane","year":"2007","unstructured":"Kane MJ, Brown LH, McVay JC, Silvia PJ, Myin-germeys I, Kwapil TR. For whom the mind wanders, and when executive control in daily life. Psychol Sci. 2007;18(7):614\u201321 http:\/\/journals.sagepub.com\/doi\/pdf\/10.1111\/j.1467-9280.2007.01948.x.","journal-title":"Psychol Sci"},{"issue":"1","key":"4022_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymgme.2016.02.004","volume":"118","author":"SE Christ","year":"2016","unstructured":"Christ SE, Price MH, Bodner KE, Saville C, Moffitt AJ, Peck D. Morphometric analysis of gray matter integrity in individuals with early-treated phenylketonuria. Mol Genet Metab. 2016;118(1):3\u20138.","journal-title":"Mol Genet Metab."},{"issue":"5","key":"4022_CR20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/028418501127347179","volume":"42","author":"M Dezortov\u00e1","year":"2001","unstructured":"Dezortov\u00e1 M, H\u00e1jek M, Tint\u011bra J, Hejcmanov\u00e1 L, Sykov\u00e1 E. MR in phenylketonuria-related brain lesions. Acta Radiol. 2001;42(5):459\u201366.","journal-title":"Acta Radiol."},{"issue":"S2","key":"4022_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10545-008-0978-7","volume":"31","author":"M Bik-Multanowski","year":"2008","unstructured":"Bik-Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis. 2008;31(S2):415\u20138 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18956249.","journal-title":"J Inherit Metab Dis"},{"issue":"SUPPL","key":"4022_CR22","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ymgme.2009.10.005","volume":"99","author":"PJ Anderson","year":"2009","unstructured":"Anderson PJ, Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab. 2009;99(SUPPL):S3\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.005.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"4022_CR23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000204415.39853.4a","volume":"66","author":"B P\u00e9rez-Due\u00f1as","year":"2006","unstructured":"P\u00e9rez-Due\u00f1as B, Pujol J, Soriano-Mas C, Ortiz H, Artuch R, Vilaseca MA, et al. Global and regional volume changes in the brains of patients with phenylketonuria. Neurol Int. 2006;66(7):1074\u20138 http:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-33646115442&partnerID=40&md5=1c59bdc45e736438aacef75e827b5179.","journal-title":"Neurol Int."},{"key":"4022_CR24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nicl.2013.08.012","volume":"3","author":"SE Christ","year":"2013","unstructured":"Christ SE, Moffitt AJ, Peck D, White DA. The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. NeuroImage Clin. 2013;3:539\u201347.","journal-title":"NeuroImage Clin"},{"issue":"SUPPL","key":"4022_CR25","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ymgme.2009.09.014","volume":"99","author":"SE Christ","year":"2010","unstructured":"Christ SE, Moffitt AJ, Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol Genet Metab. 2010;99(SUPPL):S33\u201340. https:\/\/doi.org\/10.1016\/j.ymgme.2009.09.014.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"4022_CR26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1005621727560","volume":"23","author":"V Leuzzi","year":"2000","unstructured":"Leuzzi V, Bianchi MC, Tosetti M, Carducci CL, Carducci CA, Antonozzi I. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. J Inherit Metab Dis. 2000;23(6):563\u201370 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11032331.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4022_CR27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/adc.2006.104786","volume":"292","author":"S Channon","year":"2007","unstructured":"Channon S, Goodman G, Zlotowitz S, Mockler C, Lee PJ. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch Dis Child. 2007;292(3):213\u20138 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17068073.","journal-title":"Arch Dis Child"},{"key":"4022_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-010-9253-9","volume":"34","author":"AE ten Hoedt","year":"2010","unstructured":"ten Hoedt AE, de Sonneville LMJ, Francois B, ter Horst NM, Janssen MCH, Estela Rubio-Gozalbo M, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2010;34:165\u201371 www.childrensmemorial.org\/.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"4022_CR29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29025426.","journal-title":"Orphanet J Rare Dis"},{"key":"4022_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgmr.2015.12.004","volume":"6","author":"CS Brown","year":"2016","unstructured":"Brown CS, Lichter-Konecki U. Phenylketonuria (PKU): a problem solved? Mol Genet Metab Reports. 2016;6:8\u201312. https:\/\/doi.org\/10.1016\/j.ymgmr.2015.12.004.","journal-title":"Mol Genet Metab Reports"},{"issue":"2\u20133","key":"4022_CR31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ymgme.2010.06.006","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Leviton L. Reaching out to the lost generation of adults with early-treated phenylketonuria (PKU). Mol Genet Metab. 2010;101(2\u20133):146\u20138.","journal-title":"Mol Genet Metab."},{"key":"4022_CR32","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A Chan","year":"2013","unstructured":"Chan A, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"3","key":"4022_CR33","first-page":"87","volume":"81","author":"Y Guigoz Epalinges","year":"2011","unstructured":"Guigoz Epalinges Y. Dietary proteins in humans: basic aspects and consumption in Switzerland. Int J Vitam Nutr Res. 2011;81(3):87\u2013100.","journal-title":"Int J Vitam Nutr Res."},{"issue":"11","key":"4022_CR34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/0026-0495(90)90095-T","volume":"39","author":"TS Burns","year":"1990","unstructured":"Burns TS, Stargel WW, Hurwitz A. Bioavailability of phenylalanine and aspartate from aspartame (20 mg\/kg) in capsules and solution. Metabolism. 1990;39(11):1200\u20133 https:\/\/www.sciencedirect.com\/science\/article\/pii\/002604959090095T.","journal-title":"Metabolism"},{"issue":"4","key":"4022_CR35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2009.07.016","volume":"98","author":"EL MacLeod","year":"2009","unstructured":"MacLeod EL, Gleason ST, van Calcar SC, Ney DM. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab. 2009;98(4):331\u20137.","journal-title":"Mol Genet Metab."},{"key":"4022_CR36","first-page":"3160","volume":"96","author":"S Kaufman","year":"1999","unstructured":"Kaufman S. A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. Med Sci. 1999;96:3160\u20134.","journal-title":"Med Sci"},{"key":"4022_CR37","volume-title":"Testbatterie zur Aufmerksamkeitspr\u00fcfung","author":"P Zimmermann","year":"2009","unstructured":"Zimmermann P, Fimm B. Testbatterie zur Aufmerksamkeitspr\u00fcfung. W\u00fcrselen: Psytest; 2009."},{"key":"4022_CR38","first-page":"498","volume-title":"Wechsler adult intelligence scale - fourth edition (WAIS-IV)","author":"D Wechsler","year":"2008","unstructured":"Wechsler D. Wechsler adult intelligence scale - fourth edition (WAIS-IV). 22nd ed. San Antonio: NCS Pearson; 2008. p. 498.","edition":"22"},{"key":"4022_CR39","unstructured":"Delis DC, Kaplan E, Kramer JH. D-KEFS: examiners manual. San Antonio: The Psychological Corporation; 2001."},{"issue":"3","key":"4022_CR40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/h0061266","volume":"32","author":"J Tiffin","year":"1948","unstructured":"Tiffin J, Asher EJ. The Purdue Pegboard: norms and studies of reliability and validity. J Appl Psychol. 1948;32(3):234\u201347.","journal-title":"J Appl Psychol"},{"issue":"7","key":"4022_CR41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/s-2004-834727","volume":"55","author":"C Albani","year":"2005","unstructured":"Albani C, Blaser G, Geyer M, Schmutzer G, Br\u00e4hler E, Bailer H, et al. \u00dcberpr\u00fcfung der G\u00fctekriterien der deutschen Kurzform des Fragebogens Profile of Mood States (POMS) in einer repr\u00e4sentativen Bev\u00f6lkerungsstichprobe. Psychother Psychosom Med Psychol. 2005;55(7):324\u201330.","journal-title":"Psychother Psychosom Med Psychol."},{"issue":"2","key":"4022_CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1040-3590.10.2.83","volume":"10","author":"DJA Dozois","year":"1998","unstructured":"Dozois DJA, Dobson KS, Ahnberg JL. A psychometric evaluation of the Beck Depression Inventory-II. Psychol Assess. 1998;10(2):83\u20139.","journal-title":"Psychol Assess."},{"issue":"1","key":"4022_CR43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13023-015-0261-6","volume":"10","author":"A Regnault","year":"2015","unstructured":"Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients \u2019 and parents \u2019 quality of life : the phenylketonuria \u2013 quality of life (PKU-QOL) questionnaires. Orphanet J Rare Dis. 2015;10(1):59.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4022_CR44","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1523\/JNEUROSCI.1770-15.2016","volume":"36","author":"K Fujiyoshi","year":"2016","unstructured":"Fujiyoshi K, Hikishima K, Nakahara J, Tsuji O, Hata J, Konomi T, et al. Application of q-space diffusion MRI for the visualization of white matter. J Neurosci. 2016;36(9):2796\u2013808 http:\/\/www.jneurosci.org\/cgi\/doi\/10.1523\/JNEUROSCI.1770-15.2016.","journal-title":"J Neurosci"},{"issue":"4","key":"4022_CR45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mrm.22708","volume":"65","author":"G \u00d6z","year":"2011","unstructured":"\u00d6z G, Tk\u00e1\u010d I. Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem. Magn Reson Med. 2011;65(4):901\u201310 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21413056.","journal-title":"Magn Reson Med"},{"issue":"8","key":"4022_CR46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/13803395.2014.953039","volume":"36","author":"LM Jacola","year":"2014","unstructured":"Jacola LM, Willard VW, Ashford JM, Ogg RJ, Scoggins MA, Jones MM, et al. Clinical utility of the N-back task in functional neuroimaging studies of working memory. J Clin Exp Neuropsychol. 2014;36(8):875\u201386.","journal-title":"J Clin Exp Neuropsychol."},{"issue":"1","key":"4022_CR47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/mrm.21983","volume":"62","author":"R Kreis","year":"2009","unstructured":"Kreis R, Zwygart K, Boesch C, Nuoffer J-M. Reproducibility of cerebral phenylalanine levels in patients with phenylketonuria determined by 1 H-MR spectroscopy. Magn Reson Med. 2009;62(1):11\u20136 http:\/\/doi.wiley.com\/10.1002\/mrm.21983.","journal-title":"Magn Reson Med"},{"issue":"24","key":"4022_CR48","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, CONSORT Group. Reporting of noninferiority and equivalence randomized trials. JAMA. 2012;308(24):2594 http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2012.87802.","journal-title":"JAMA"},{"issue":"6","key":"4022_CR49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10545-010-9043-4","volume":"33","author":"F Feillet","year":"2010","unstructured":"Feillet F, Agostoni C. Nutritional issues in treating phenylketonuria. J Inherit Metab Dis. 2010;33(6):659\u201364.","journal-title":"J Inherit Metab Dis."},{"issue":"1","key":"4022_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.03.002","volume":"121","author":"DA Bilder","year":"2017","unstructured":"Bilder DA, Kobori JA, Cohen-Pfeffer JL, Johnson EM, Jurecki ER, Grant ML. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab. 2017;121(1):1\u20138.","journal-title":"Mol Genet Metab."},{"key":"4022_CR51","doi-asserted-by":"crossref","unstructured":"Hollak CE, Lachmann R. (Eds.). Inherited Metabolic Disease in Adults: A Clinical Guide. Oxford University Press; 2016.","DOI":"10.1093\/med\/9780199972135.001.0001"},{"issue":"4","key":"4022_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/87565641.2016.1243109","volume":"41","author":"DA Bilder","year":"2016","unstructured":"Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, Merilainen MJ, et al. systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria. Dev Neuropsychol. 2016;41(4):245\u201360. https:\/\/doi.org\/10.1080\/87565641.2016.1243109.","journal-title":"Dev Neuropsychol"},{"issue":"5","key":"4022_CR53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/01688639408402681","volume":"16","author":"E Schmidt","year":"1994","unstructured":"Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level*. J Clin Exp Neuropsychol. 1994;16(5):681\u20138.","journal-title":"J Clin Exp Neuropsychol."},{"key":"4022_CR54","volume-title":"FDA approves new treatment for a rare genetic disorder, Fabry disease","author":"FDA","year":"2018","unstructured":"FDA. FDA approves new treatment for a rare genetic disorder, Fabry disease. 2018; https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm608835.htm. Cited 28 Sept 2018."},{"key":"4022_CR55","volume-title":"EMEA-001951-PIP01\u201316 | European Medicines Agency","author":"EMEA","year":"2018","unstructured":"EMEA. EMEA-001951-PIP01\u201316 | European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/medicines\/human\/paediatric-investigation-plans\/emea-001951-pip01-16. Accessed 28 Sept 2018."},{"issue":"4","key":"4022_CR56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2018.06.002","volume":"124","author":"HL Levy","year":"2018","unstructured":"Levy HL, Sarkissian CN, Scriver CR. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria. Mol Genet Metab. 2018;124(4):223\u20139 https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218302920.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4022_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2018.03.003","volume":"24","author":"J Jiang","year":"2018","unstructured":"Jiang J, Amato RS, Weng HH, Burton BK, Stuy M, Longo N, et al. Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol Genet Metab. 2018;24(1):20\u20136. https:\/\/doi.org\/10.1016\/j.ymgme.2018.03.003.","journal-title":"Mol Genet Metab"},{"key":"4022_CR58","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ymgme.2018.03.006","volume":"124","author":"J Thomas","year":"2018","unstructured":"Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, et al. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124:1096\u20137192 http:\/\/creativecommons.org\/licenses\/BY\/4.0\/.","journal-title":"Mol Genet Metab"}],"updated-by":[{"DOI":"10.1186\/s13063-020-04489-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-4022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-4022-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-4022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T09:02:55Z","timestamp":1665824575000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-4022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-4022-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9834\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9834\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"17 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research project has been approved by the ethics committee of the canton of Bern, Switzerland (KEK BE 2018\u201301609). Important study protocol modifications will be reported to the relevant parties. In addition, the research project is registered at in online platforms (\n                      \n                      and kofam.ch).After being verified as eligible for the study, the participants will receive adequate verbal information about the study. They will be given enough time to consider their participation, and the informed consent form will be sent to them. Written informed consent will be obtained of all participants by the study physician (R.T.) or the study coordinators (R.M., S.A.). Participants can withdraw from participating at any time without giving a reason. If participants discontinue, their data will still be analyzed. Individual medical information obtained as a result of this study is considered confidential, and disclosure to third parties is prohibited. Participants\u2019 confidentiality will be further ensured by utilizing subject identification code numbers (both on paper and electronically) to correspond to treatment data in the computer files. The key (i.e., a list in which an alphanumeric code is linked to individual participants\u2019 names) will be kept separately from the study data in a secured (locked) document. Access to documents, datasets, statistical codes, etc. during and after the study will only be granted to the PI and his designees (e.g., co-authors of the study protocol). The results of the present study will be submitted for publication in peer-reviewed journals and will be presented at national and international scientific meetings to healthcare professionals and\/or the public. Authorship eligibility will be determined according to the Vancouver Convention established by the International Committee of Medical Journal Editors (ICMJE).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}